Weekly vs. Three-Weekly Docetaxel for Breast Cancer
Author Information
Author(s): Walker Leslie G, Eremin Jennifer M, Aloysius Mark M, Vassanasiri Wichai, Walker Mary B, El-Sheemy Mohamed, Cowley Ged, Beer Jeanette, Samphao Srila, Wiseman Janice, Jibril Jibril A, Valerio David, Clarke David J, Kamal Mujahid, Thorpe Gerald W, Baria Karin, Eremin Oleg
Primary Institution: Oncology Health Centres and the Institute of Rehabilitation, University of Hull
Hypothesis
Does weekly docetaxel improve quality of life compared to three-weekly docetaxel in women undergoing neoadjuvant chemotherapy for breast cancer?
Conclusion
Weekly docetaxel is well-tolerated and has less distressing side effects, without compromising therapeutic responses, breast conserving surgery, or survival outcomes.
Supporting Evidence
- Patients receiving weekly docetaxel reported less constipation, nail problems, neuropathy, tiredness, distress, depressed mood, and unhappiness.
- There were no significant differences in overall clinical response rates between the two treatment groups.
- Both treatment regimens resulted in similar disease-free survival and overall survival rates.
Takeaway
This study looked at two ways to give a cancer drug to women with breast cancer. The weekly way was easier on the patients, but both ways worked about the same.
Methodology
Eighty-nine patients were randomized to receive either twelve cycles of weekly docetaxel or four cycles of three-weekly docetaxel after four cycles of doxorubicin and cyclophosphamide.
Potential Biases
Potential biases in patient selection and self-reported quality of life measures.
Limitations
The study had a small sample size and may not be generalizable to all breast cancer patients.
Participant Demographics
Women aged 18-70 with large or locally advanced breast cancer.
Statistical Information
P-Value
0.86
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website